Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 1 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ildong Pharmaceutical Co. Ltd. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners. All 4 examiners are located within 1 distinct art unit, which indicates a high degree of administrative concentration for the company's active matters. This structure may lead to more consistent examination results than if the matters were spread across multiple units.
The busiest examiner for the portfolio is HUI, SAN MING R, who handles 1 pending office action. With 4 pending office actions and 4 distinct examiners, each examiner is responsible for a single case. Practitioners will need to interact with four different individuals, but the fact that they all work within 1 distinct art unit may suggest a consistent application of policies for the company's biotechnology applications. This structure centralizes the prosecution environment despite the involvement of multiple examiners. The presence of 4 pending office actions reflects an active engagement with the patent office within a single specialized group.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| JAVANMARD, SAHAR | 1 | 64.8% | +34.1% |
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719710 | NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | JAVANMARD, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557538 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | KUCKLA, ANNA GRACE | 22d overdue |
| 18850107 | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof | HUI, SAN MING R | — |
| 18720436 | NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | NOTTINGHAM, KYLE GREGORY | — |
| 18719710 | NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | JAVANMARD, SAHAR | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850107 | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof | HUI, SAN MING R | — | §103 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18720436 | NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | NOTTINGHAM, KYLE GREGORY | — | §103DP | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18719710 | NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | JAVANMARD, SAHAR | — | §102§103§112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18557538 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | KUCKLA, ANNA GRACE | 1626 | §103 | Non-Final OA | 22d overdue | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial